Trial Profile
An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
- 23 Oct 2020 Status changed from active, no longer recruiting to completed.
- 31 Aug 2020 Planned End Date changed from 12 Aug 2020 to 28 Oct 2020.
- 15 Jan 2018 Status changed from recruiting to active, no longer recruiting.